Skip to main content

Advertisement

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

The original article was published in BMC Cancer 2019 19:517

Correction to: BMC Cancer

https://doi.org/10.1186/s12885-019-5687-0

Following publication of the original article [1], the authors reported the following errors in the article.

  1. 1)

    In Table 2, the layout has been updated. The corrected Table 2 is supplied below:

  2. 2)

    The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows:

  3. 3)

    The competing interests statement has been updated below.

Table 2 Progression-free survival by HER2 expression subgroups
Fig. 3
figure1

Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.*

*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine

Reference

  1. 1.

    Perez, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2- positive advanced breast cancer. BMC Cancer. 2019;19:517 https://doi.org/10.1186/s12885-019-5687-0.

Download references

Author information

Correspondence to Edith A. Perez.

Ethics declarations

Competing interests

EAP was a salaried employee of Genentech, Inc. at the time this work was prepared and owns stock in F. Hoffmann-La Roche Ltd. SLdH, SS, and MP are salaried employees of F. Hoffmann-La Roche Ltd. SS and MP own stock in F. Hoffmann-La Roche Ltd. WE has served as a consultant and on Speakers’ Bureaus for F. Hoffmann-La Roche Ltd. CHB has served as a consultant for F. Hoffmann-La Roche Ltd., Pfizer, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and Eisai and has received research funding from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, F. Hoffmann-La Roche/Genentech, Eisai, Lilly, Sanofi-Aventis, and Celgene. MT has received research funding from Chugai Pharmaceutical. PFC has served on Speakers’ Bureaus for Novartis, F. Hoffmann-La Roche Ltd., and AstraZeneca and has received research funding from F. Hoffmann-La Roche Ltd. and Novartis. MM has received honoraria from and has served as a consultant for F. Hoffmann-La Roche Ltd. TP has received honoraria and research funding from F. Hoffmann-La Roche Ltd., Pfizer, and Novartis. He has also served as a consultant for F. Hoffmann-La Roche Ltd. XBP has received honoraria from F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Amgen, Novartis, Pierre Fabre, and Eisai. He has also served as a consultant for F. Hoffmann-La Roche Ltd., Amgen, Novartis, Pierre Fabre, and Eisai. Y-HI, HAB, and PAE have nothing to disclose.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark